MAPLE GROVE, Minn., April 12, 2024 /PRNewswire/ -- Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be participating in the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, from April 13 to 18, 2024. Representatives from Upsher-Smith will be on hand at Booth #818 to showcase its expanding portfolio of medications backed by the Promise of Support™ Program, including the VIGADRONE® (vigabatrin) product family and TORPENZ™ (everolimus) Tablets slated for availability in mid-2024.
Pyros Pharmaceuticals Announces VIGPODER™ (vigabatrin) is Now Available
Pyros Announces Positive Outcome of the Procedure for Approval of VIGZIP
InvaGen Pharmaceuticals Issues Voluntary Nationwide Recall of Vigabatrin for Oral Solution, USP 500mg due to Leaking Sachets
HAUPPAUGE, N.Y., Dec. 9, 2023 /PRNewswire/ -- Cipla Limited today announced that its wholly-owned subsidiary, InvaGen Pharmaceuticals Inc., USA is voluntarily recalling one lot of Vigabatrin for Oral Solution, USP 500mg, to the consumer level. Vigabatrin for Oral Solution, USP 500 mg has been found to have seal integrity issues allowing for powder leakage from the pouch.
InvaGen Issues Voluntary Nationwide Recall of Vigabatrin for Oral Solution
Health Canada Issues Recall of Sabril (vigabatrin) 500 mg sachets found to contain trace amounts of another drug
Enforcement Report - Week of September 6, 2023
Enforcement Report - Week of March 8, 2023
MSN's Generic Vigabatrin Receives Approval in the U.S.